Open Label Study: Treatment of ALS Fatigue With PolyMVA

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

May 25, 2021

Study Completion Date

May 25, 2021

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

PolyMVA

"One-half teaspoon of PolyMVA contains the following:~* Daily Value Thiamin (B-1) 23mg 1,533 Riboflavin (B-2) 0.45mg 26 Vitamin B-12 460mcg 7,666 Proprietary Blend 32mg - contains the following ingredients (no FDA value has been established on any of the following): Palladium, Alpha Lipoic Acid, Molybdenum, Rhodium, Ruthenium, Formyl Methionine, N-acetyl Cysteine.~For each ml of Poly-MVA, the exact dosages are as follows:~Palladium: 3.97mg Molybdenum: 0.044mg Ruthenium: 0.0014mg Rhodium: 0.014mg Lipoic Acid: 7.68mg Thiamine (B1): 9.26mg Riboflavin (B2): 0.174mg B12: 0.185mg Formyl Methionine: 0.026mg N-Acetyl cysteine: 0.185mg Vitamin A acetate 100 IU~Other Ingredients: Distilled water, purified water, thiamine hydrochloride, Vitamin B12 as cyanocobalamin."

Trial Locations (1)

65212

University of Missouri-Columbia School of Medicine, Columbia

All Listed Sponsors
collaborator

Band of Hope Foundation

UNKNOWN

lead

University of Missouri-Columbia

OTHER

NCT04557410 - Open Label Study: Treatment of ALS Fatigue With PolyMVA | Biotech Hunter | Biotech Hunter